The gut microbiome has been associated with a growing list of diseases. Drugs and other 13 compounds can affect the microbiome, but our understanding of drug-induced changes in 14 individual microbiomes is limited due to a lack of rapid and effective high-throughput assay 15 methods. We developed an approach named Rapid Assay of Individual Microbiome (RapidAIM) 16 to screen xenobiotics against individual microbiomes. RapidAIM was evaluated by testing 43 17 compounds against five individual microbiomes using a metaproteomic approach. We show that 18 our workflow enables quantitative profiling of the microbiome. The tested compounds 19 significantly affected overall microbiome abundance, microbiome composition and functional 20 pathways at multiple taxonomic levels. The microbiome responses to berberine, metformin, 21 diclofenac, fructooligosaccharide and most antibiotics were consistent among most individuals.
metaproteomics techniques [19] [20] [21] . First, to validate the relative quantification of total bacterial 88 biomass by comparing total peptide intensity, an equal volume of samples from a microbiome 89 dilution series (simulating different levels of drug effects) was taken for tryptic digestion and 90 LC-MS/MS analysis. Summed peptide intensity in each sample showed good linearity (R 2 = 91 0.991, Figure 1b ) with a standard colorimetric protein assay, showing that the total peptide 92 intensity is a good indicator for microbiome biomass levels. We then evaluated whether biomass 93 differences between wells could cause identification bias. We confirmed that the level of total 94 biomass didn't bias data quantifications, including functional profiles (Figure 1c) , protein group 95 quantifications (Supplementary Figure S2a) , and taxonomic biomass contributions 17 96 (Supplementary Figure S2b ).
97
RapidAIM: Proof-of-concept study 98 We conducted a proof-of-concept (POC) study on the use of RapidAIM to characterize drug-99 microbiome interactions. We selected 43 compounds that have been previously shown to impact 100 or interact with the gut microbiome ( Supplementary Table S1 ). Thirty-seven of these Within each individual microbiome group, a number of drug-treated samples clustered closely to 117 their control while several drug-treated samples clearly separated from the non-treated control. 118 We next evaluated the robustness and reproducibility of the method by culturing one microbiome 119 with drugs in technical triplicates. Cultured triplicates yielded high Pearson's r for LFQ protein 120 group intensities (Figure 1d ). Hierarchical clustering based on Pearson's r of LFQ protein group 121 intensities between samples showed that with the exception of several compounds which 122 clustered closely with DMSO, cultured triplicates were clustered together (Supplementary 123 Figure S3a ). Moreover, total biomass, functional enzymes, and species biomass contributions 124 were highly reproducible between triplicates as shown in Supplementary Figure S3b-d . 125 Finally, we assessed whether RapidAIM recapitulates known in vivo microbiome responses to 147 We examined the effect of the 43 compounds on the overall abundance (biomass) of each 148 individual microbiome by comparing the total peptide intensity (Figure 2a ). As expected, the 149 antibiotics rifaximin, ciprofloxacin and metronidazole greatly reduced total microbial biomass in 150 most individual microbiomes. Berberine, ibuprofen, isoniazid, diclofenac and indomethacin also 151 mildly inhibited the biomass of all individual microbiomes. 152 We next explored the effects of drugs on the microbiome composition. We first took a Wilcoxon test, FDR-adjusted p < 0.05; Figure 2c ). 163 In addition to the overall shifts in microbiome composition, we examined the biomass of 164 individual bacterial species in the microbiomes. We found that 36 of the 43 compounds 165 significantly affected the biomass of at least one bacterial species (one-sided Wilcoxon rank sum 166 test, FDR-adjusted p < 0.05; Supplementary Table S2 ). We then compared the bacterial 167 response we observed in microbiome cultures to the response reported in a previous study of 168 isolated bacterial cultures 11 . Besides the antibiotics, six of the compounds we tested 169 (methotrexate, azathioprine, mercaptopurine, simvastatin, flucytosine, and digoxin) were 170 previously shown to have antibiotic-like effects on isolated bacterial strains 11 . In response to 171 these six compounds, our microbiome-based assay suggested four significant inhibitions which 172 were also found in the isolated culture-based study 11 (blue boxes with orange stars, 173 Supplementary Figure S5 ). Furthermore, we found 11 other significant responses (orange 174 boxes, Supplementary Figure S5 ) that were not detected in the isolated culture-based study 11 . intensity between compound and DMSO control samples was calculated for each individual 181 microbiome (for full compound names, see abbreviation list in Supplementary Table S1 
Effects of compounds on microbiome abundance and composition

Detection of three main classes of compounds 189
To gain a better understanding of the global effects of xenobiotics on the gut microbiome, we Figure S6 ). We 216 identified 535 COGs significantly decreased by at least one drug treatment; 15 of these COGs 217 were decreased by ≥ 10 compounds (Supplementary Figure S6 ). Diclofenac and FOS were the 218 only two compounds that significantly increased COGs (55 and 81 COGs, respectively). COG 219 categories found to be significantly enriched were responsive to 13 of the drugs tested ( Figure   220 4b). Notably, 7 of the 13 drugs were class I compounds. In addition, the non-antibiotic NSAID 221 diclofenac increased the abundance of the COG categories G (carbohydrate transport and 222 metabolism), F (nucleotide transport and metabolism), E (amino acid transport and metabolism), 223 and O (posttranslational modification, protein turnover, chaperones) (Figure 4b ). Next, we 224 mapped the significantly increased proteins from these COG categories against the string 225 database (Supplementary Figure S7) . Interestingly, one of the proteins that were highly 226 connected in the string network, COG0176transaldolase (1.76 ± 0.21 fold-change), is involved 227 in the biosynthesis of ansamycins, bacterial secondary metabolites that have antibiotic 228 activities 33 . This could be part of the mechanism causing the decline in total biomass (Figure 2a ) 229 and shift in microbiome composition in the presence of diclofenac (Figure 2c ). In the present study we developed an approach named Rapid Assay of Individual Microbiome representative gut bacteria isolates 11 were replicated in our study, we identified additional 340 responses that were not reported in bacterial isolates 11 . For example, the biomass of the 341 opportunistic pathogen C. difficile was decreased by azathioprine treatment in our study, but this 342 effect was not shown with bacterial isolates 11 . Although some differences in bacterial responses 343 between the two studies might be due to variation at the strain level, the discrepancies suggest 344 that the microbial community plays an important role in the response of individual microbes. As 345 an example, community resistance mechanisms allow members of a bacterial community to 346 survive antibiotic exposures that would be lethal to individual isolates 12 .
347
In addition to affecting microbiome biomass, our test compounds altered metaproteomic 348 composition. Although additional studies are needed to test a broader range of compounds, our 349 proof of concept study has identified three different classes of drug effects on the microbiome.
350
Seven of our 43 compounds had strong functional effects that were globally similar across number of drugs could also directly affect the gut microbiome in the absence of a host 362 mechanism. 363 We showed that the RapidAIM assay yielded insights into functional responses at multiple 364 taxonomic levels. Using PLS-DA, we found that berberine, FOS, metronidazole, isoniazid, with several reports indicating that ciprofloxacin triggers oxidative stress in several bacteria [40] [41] [42] . 377 With berberine treatment, we showed that taxon-specific functional shifts can occur either with pre-reduced with 0.1% (w/v) L-cysteine hydrochloride, a 2.5 ml sterile sampling spoon (Bel-Art, 415 United States), plastic wrap, gloves and disposal bags. Briefly, each volunteer placed the plastic 416 wrap over a toilet to prevent the stool from contacting water, collected ~3 g of stool with the 417 sampling spoon, and dropped the spoon into the prepared 50 ml tube. The sample was 418 immediately weighed by a researcher and transferred into an anaerobic workstation (5% H2, 5% 419 CO2, and 90% N2 at 37°C), where the tube was uncapped to remove O2 before homogenization 420 with a vortex mixer. Then the homogenate was filtered using sterile gauzes to remove large 421 particles and obtain the microbiome inoculum. confirming that these compounds still showed effect after a 10× dilution (as can be seen from 434 hierarchical clustering in Supplementary Figure S3) , the concentrations corresponding to the 435 1/10 highest oral dosages were used for these compounds. Detailed catalogue number and 436 concentration of each compound is listed in Supplementary Table S1 . After inoculation, the 96-437 well deep well plate was covered with a sterile silicone gel mat with a vent hole for each well made 438 by a sterile syringe needle. Then, the plate was shaken at 500 rpm with a digital shaker (MS3, IKA, 439 Germany) at 37 o C for 24 hours in the anaerobic chamber. 441 We used a previously reported metaproteomic sample processing workflow 18 , adapted for 442 microplates. After culturing for 24 hr, each 96-well plate was transferred out of the anaerobic 443 station and was immediately centrifuged at 300 g for 5 min to remove debris. The supernatants 444 were transferred into new 96-well deep well plates for another two rounds of debris removal at 445 300 g. The supernatants were then transferred to a new plate and centrifuged at 2,272 g for 1 hr 446 to pellet the microbiome. The supernatant was removed and the pelleted bacterial cells were 447 washed three times with cold PBS in the same 96-deep well plate, pelleting the cells after each Microplate-based metaproteomic sample preparation: 478 Due to a few differences in the metaproteomic procedure compared with previously published 479 tube-based ones 47,48 , we examined the effect of protocol differences on sample quality at each 480 step. Detailed procedures are described in Supplementary Figure S1 . 481 Equal-volume strategy: 482 Six dilutions of a single microbiome sample were prepared in triplicate wells and an equal 483 volume was taken from each sample for tryptic digestion and LC-MS/MS analysis.
440
Metaproteomic sample processing and LC-MS/MS analysis
484
Metaproteomic sample processing and analysis followed the same procedures stated above, and 485 total peptide intensity was calculated. A DC protein concentration assay was also performed with 486 each sample. Linearity between total protein concentration and total peptide intensity quantified 487 by LC-MS/MS was then compared. Due to a few differences in the metaproteomic procedure compared with tube-based protocols, we 745 examined the effect of protocol differences on sample quality step-by-step. In previously published 746 protocols, samples were cultured in 2 ml culture tubes 1,2 . In step [1], culturing samples in a 96-well plate 747 reduced the sample size to 1 ml. No significant difference was shown by t-test in peptide and protein 748 group identification numbers between protein extractions from 1 ml and 2 ml samples. For step [2] , the 749 96-deepwell plates limited centrifugation speed to 2,270 g (versus 14,000 g in the original protocol), so 750 we extended the centrifugation time from 20 min to 1 hour and tested whether bacterial concentration was 751 affected by the altered centrifugation process 1,3 . Concentration of purified bacterial cells were compared 752 by OD600 after being re-suspended in 1 ml, 2 ml, 4 ml, 8 ml, and 16 ml PBS. No significant difference in 753 OD600 reads was observed between the two cell purification protocols. In step [3] , the original protocol 754 used a high-speed centrifugation (16,000 g) to remove cell debris after the ultrasonication. Due to the 755 limitation of centrifugation speed when using a microplate, we compared metaproteomic profiles of the 756 sample when digested with or without cell debris removal. No significant differences were found in the 757 number of protein identifications. In terms of differentially identified proteins, we found that the samples 758 without cell debris removal resulted in more identifications of cell-membrane proteins such as the ABC-759 type transport systems, as well as cytoskeleton-related proteins, such as the translation elongation factor 760 EF-Tu 4,5 , 6-phosphofructokinase 6 , and ribosomes 7 . Therefore, we infer that eliminating the 761 centrifugation process could reduce the removal of cytoskeleton and cell membrane proteins. For step [4], 762 no validation was necessary as the same type of filter tips were used in both protocols. Finally, we 763 performed a whole-workflow comparison of the metaproteomic outcomes between traditional tube-based 764 and 96-well-based processes. The microplate-based metaproteomic workflow showed no statistically 765 significant difference in peptide and protein identification compared with the tube-based workflow. 
